2024
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids
Al-Hendy A, Segars J, Taylor H, González F, Siblini H, Zamah M, Alkelani H, Singh B, Flores V, Christman G, Johnson J, Huang H, Zhang H. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open 2024, 14: e078989. PMID: 38216200, PMCID: PMC10806662, DOI: 10.1136/bmjopen-2023-078989.Peer-Reviewed Original ResearchConceptsUnexplained infertilityIntrauterine inseminationInstitutional review boardCumulative live birth rateUterine fibroidsLive birth rateCause of infertilityFood and Drug AdminstrationGonadotropin hormone-releasing hormoneGreen tea extractDouble-blind clinical trialNon-surgical treatment optionsTimed intrauterine inseminationUterine fibroid sizeOvarian stimulationQuality of Life Questionnaire scoresHormone-releasing hormoneLocal institutional review boardInfertility treatmentNational Institute of Child HealthInstitute of Child HealthMiscarriage rateBirth rateReproductive-age womenEndometrial quality
2022
Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial
Legro RS, Hansen KR, Diamond MP, Steiner AZ, Coutifaris C, Cedars MI, Hoeger KM, Usadi R, Johnstone EB, Haisenleder DJ, Wild RA, Barnhart KT, Mersereau J, Trussell JC, Krawetz SA, Kris-Etherton PM, Sarwer DB, Santoro N, Eisenberg E, Huang H, Zhang H, . Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial. PLOS Medicine 2022, 19: e1003883. PMID: 35041662, PMCID: PMC8765626, DOI: 10.1371/journal.pmed.1003883.Peer-Reviewed Original ResearchConceptsHealthy live birthIntensive lifestyle interventionLifestyle interventionLive birthsWeight lossExercise interventionPrimary outcomeBirth outcomesMetabolic healthInfertility treatmentPhysical activityOvarian stimulation/intrauterine inseminationIntensive groupFirst trimester pregnancy lossIntensive lifestyle groupLifestyle modification groupPreconception lifestyle interventionStandard exercise interventionAcute weight lossTrimester pregnancy lossGastrointestinal side effectsSignificant weight lossLive birth incidenceLifestyle groupUnexplained infertility
2020
Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins
Legro RS, Diamond MP, Coutifaris C, Schlaff WD, Alvero R, Casson P, Christman GM, Rosen RM, Cedars MI, Hansen KR, Robinson R, Baker V, Usadi R, Dodson WC, Estes SJ, Kunselman A, Stetter C, Barnhart KT, Coward RM, Trussell JC, Krawetz SA, Santoro N, Huang H, Zhang H, Eisenberg E, Network R. Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins. Fertility And Sterility 2020, 113: 1005-1013. PMID: 32386612, PMCID: PMC7376442, DOI: 10.1016/j.fertnstert.2019.12.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsChild BehaviorChild DevelopmentChild, PreschoolClomipheneCognitionFemaleFertilityFertility AgentsFollow-Up StudiesGesturesGonadotropinsHumansInfantInfertility, FemaleLetrozoleLive BirthMaleOvulation InductionPolycystic Ovary SyndromePregnancyProspective StudiesRandomized Controlled Trials as TopicRegistriesTreatment OutcomeUnited StatesWeight GainConceptsGN groupMultiple pregnancy rateProspective cohort studyPolycystic ovary syndromeChildren of womenInfertility trialsUnexplained infertilityCohort studyII studyMultiple gestationsOvary syndromeHealth centersInfertility treatmentPregnancy rateInfertility therapyMAIN OUTCOMELTZ groupLetrozoleMacArthur-Bates Communicative Development InventoriesAcademic health centersGonadotropinAbnormal scoresClomipheneCC groupDevelopmental Questionnaire